Table 1.
Baseline characteristics
| Characteristic | Total | De novo AML | Secondary AML | p value |
|---|---|---|---|---|
| Number of patients | 52 | 40 | 12 | NA |
| Age, yr | 62 (23–88) | 63 (23–88) | 60 (40–81) | 0.656 |
| ≤ 65 | 33 (63.5) | 26 (65.0) | 7 (58.3) | |
| > 65 | 19 (36.5) | 14 (35.0) | 5 (41.7) | |
| Sex, male | 33 (63.5) | 26 (65.0) | 7 (58.3) | 0.674 |
| Cytogenetic risk | ||||
| Low | 6 (11.5) | 6 (15.0) | 0 (0.0) | 0.001 |
| Intermediate | 38 (73.1) | 32 (80.0) | 6 (50.0) | |
| High | 8 (15.4) | 2 (5.0) | 6 (50.0) | |
| Combined riska | ||||
| Low | 7 (13.5) | 7 (17.5) | 0 | 0.037 |
| Intermediate | 19 (36.5) | 15 (37.5) | 4 (33.3) | |
| High | 12 (23.1) | 6 (15.0) | 6 (50.0) | |
| Unknown | 14 (26.9) | 12 (30.0) | 2 (16.7) | |
| Extramedullary involve | 0 | 0 | 0 | NA |
| Laboratory findings | ||||
| Bone marrow blast, % | 63.7 ± 22.4 | 66.5 ± 20.2 | 54.5 ± 27.6 | 0.281 |
| WBC count, /L | 29,169 ± 54,648 | 31,740 ± 61,259 | 20,599 ± 20,903 | 0.334 |
| Platelet count, × 109/L | 86.1 ± 72.0 | 81.3 ± 52.5 | 102.1 ± 117.9 | 0.564 |
| Hemoglobin, g/dL | 9.2 ± 2.0 | 9.0 ± 2.0 | 9.8 ± 2.2 | 0.292 |
Values are presented as median (range), number (%), or mean ± standard deviation.
AML, acute myeloid leukemia; NA, not applicable; WBC, white blood cell.
a
Combined risk refers to risk stratification based on available next generation sequencing data including TP53, ASXL1, RUNX1 mutation status.